A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric Cancer
NCT ID: NCT01839500
Last Updated: 2018-03-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1600 participants
OBSERVATIONAL
2013-04-25
2018-01-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer
NCT02004769
Trastuzumab Based Therapy in HER2 Positive AGC
NCT03024450
Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
NCT06846996
Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System
NCT03185988
A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer
NCT01260194
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort I: HER2-Positive mGC Treated With Trastuzumab
HER2-positive metastatic gastric cancer (mGC) participants who are treated with trastuzumab will be included in this cohort. As this is an observational study, treatment schedule will be at the clinician's discretion in accordance with routine care practice and not dictated by the protocol.
Trastuzumab
Trastuzumab administered in accordance with routine care practice.
Cohort II: HER2-Positive mGC not Treated With Trastuzumab
HER2-positive mGC participants who are not treated with trastuzumab will be included in this cohort.
No interventions assigned to this group
Cohort III: HER2-Positive non-mGC
HER2-positive non-mGC participants will be included in this cohort.
No interventions assigned to this group
Cohort IV: HER2-Negative mGC
HER2-negative mGC participants will be included in this cohort.
No interventions assigned to this group
Cohort V: HER2-Negative non-mGC
HER2-negative non-mGC participants will be included in this cohort.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Trastuzumab
Trastuzumab administered in accordance with routine care practice.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Documented participant with trackable medical records
* HER2 status by immunohistochemistry (IHC) is known
* Cohort I/II/IV: Participants with mGC: with recurrent or metastatic disease or with inoperable locally advanced disease
* Cohort III/V: Participants with operable non-mGC: TxNxM0 (according to American Joint Committee on Cancer \[AJCC\] edition 7th)
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Anyang Tumor Hosptial
Anyang, , China
Cancer Hospital Chinese Academy of Medical Sciences.
Beijing, , China
Peking University First Hospital
Beijing, , China
The Affiliated Hospital of Military Medical Sciences(The 307th Hospital of Chinese PLA)
Beijing, , China
Peking University Third Hospital
Beijing, , China
Beijing Cancer Hospital
Beijing, , China
Beijing Union Hospital
Beijing, , China
General Hospital of Chinese PLA; Department of Hematology
Beijing, , China
the First Hospital of Jilin University
Changchun, , China
Hu Nan Provincial Cancer Hospital
Changsha, , China
The Second Xiangya Hospital of Central South University
Changsha, , China
Changzhou First People's Hospital
Changzhou, , China
Sichuan Provincial Cancer Hospital
Chengdu, , China
West China Hospital, Sichuan University
Chengdu, , China
Sichuan Provincial People's Hospital
Chengdu, , China
Third Affiliated Hospital of Third Military Medical University
Chongqing, , China
The First People's Hospital of Foshan
Foshan, , China
Fujian Medical University Union Hospital
Fujian, , China
The First Affiliated Hospital of Fujian Medical University
Fuzhou, , China
Fujian Provincial Hospital
Fuzhou, , China
Sun Yat-sen Memorial Hospital
Guangzhou, , China
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, , China
Nanfang Hospital, Southern Medical University
Guangzhou, , China
Guizhou Provincial People's Hospital
Guiyang, , China
Guizhou Cancer Hospital
Guiyang, , China
Hainan provincial people's hospital
Haikou, , China
Cancer Hospital of Hangzhou (Wushan District)
Hangzhou, , China
Hangzhou First People's Hospital
Hangzhou, , China
Harbin Medical University Cancer Hospital
Harbin, , China
The First Affiliated Hospital of Anhui Medical University
Hefei, , China
Inner Mongolia People's Hospital
Hohhot, , China
Affiliated Hospital of Inner Mongolia Medical College
Hohhot, , China
The First Affilliated Hospital of Kunming Medical College
Kunming, , China
The First People's Hospital of Yunnan Province
Kunming, , China
Yunnan Cancer Hospital
Kunming, , China
The First Affiliated Hospital of Lanzhou University
Lanzhou, , China
Gansu Cancer Hospital
Lanzhou, , China
Taizhou Hospital of Zhejiang Province
Linhai, , China
The First Affiliated Hospital of Henan UN of Science and Technology
Luoyang, , China
The 1st Affiliated Hospital of Nanchang Unversity
Nanchang, , China
The Second Affiliated Hospital to Nanchang University
Nanchang, , China
Jiangxi Cancer Hospital; First department of abdominal surgery
Nanchang, , China
Affiliated Hospital of North Sichuan Medical College
Nanchong, , China
Nanjing 1st Hospital; Endocrinology Dept.
Nanjing, , China
Jiangsu Cancer Hospital
Nanjing, , China
Jiangsu Province Hospital
Nanjing, , China
The 81st Hospital of P.L.A.
Nanjing, , China
Affiliated Hospital of Nantong University
Nantong, , China
Nan Tong Tumor Hospital
Nantong, , China
The Affiliated Hospital of Medical College Qingdao University
Qingdao, , China
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, , China
Fudan University Shanghai Cancer Center
Shanghai, , China
Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, , China
Changhai Hospital of Shanghai
Shanghai, , China
Changhai Hospital; Oncology
Shanghai, , China
Shaoxing People's Hospital
Shaoxing, , China
Liaoning cancer Hospital & Institute
Shenyang, , China
Hebei Medical University Fourth Hospital;(Tumor Hospital of Hebei Province)
Shijiazhuang, , China
First Affiliated Hospital of Soochow University
Suzhou, , China
Shanxi Province Cancer Hospital
Taiyuan, , China
Tianjin Medical University General Hospital
Tianjin (天津), , China
The Tumor Hospital of Xinjiang Medical University
Ürümqi, , China
The First Teaching Hospital of Xinjiang Medical University
Ürümqi, , China
The Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical College
Wenzhou, , China
Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology
Wuhan, , China
Tongji Hosp, Tongji Med. Col, Huazhong Univ. of Sci. & Tech
Wuhan, , China
Zhongnan Hospital of Wuhan University
Wuhan, , China
Hubei Cancer Hospital
Wuhan, , China
Wuxi No.4 People's Hospital
Wuxi, , China
The First Affiliated Hospital of The Fourth Military Medical University (Xijing Hospital)
Xi'an, , China
The Second Affiliated Hospital of The Fourth Military Medical University (Tangdu Hospital)
Xi'an, , China
Shanxi Provincial People's Hospital
Xi'an, , China
The First Affiliated Hospital of Xiamen University
Xiamen, , China
Zhongshan Hospital Xiamen University
Xiamen, , China
Xinxiang Central Hospital
Xinxiang, , China
Northern Jangsu People's Hospital
Yangzhou, , China
Zhangzhou Municipal Hospital of Fujian Province
Zhangzhou, , China
Henan Provincial People's Hospital
Zhengzhou, , China
Henan Cancer Hospital
Zhengzhou, , China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, , China
Affiliated Hospital of Jiangsu University
Zhenjiang, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML28934
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.